Table 7.
Dendrimers applied to the treatment of systemic infections.
| Formulation | Composition | Therapeutic target | Route of administration | Reference |
|---|---|---|---|---|
| Carbosilane dendrimer | Carbosilane dendrimer + trisaccharides of globotriaosyl ceramide | Shiga toxin producing Escherichia coli O157:H7 | Intravenous | Nishikawa et al., 2002 |
| Cationic PAMAM dendrimers | dendrimer-siRNA | HIV-1 | Intravenous | Zhou et al., 2011 |
| PPI dendrimer | MdPPI dendrimer + amphotericin-B | Leishmania donovani | Intraperitoneal | Jain et al., 2015 |
| Dendrimer TNS18 | peptide dendrimers | Pseudomonas aeruginosa; Acinetobacter baumannii | Intraperitoneal | Siriwardena et al., 2018 |
| Folate-PAMAM dendrimer | PAMAM + folate + Cy5.5 conjugate | Chlamydia trachomatis | Intravenous | Benchaala et al., 2014 |
| PAMAM dendrimer (G4OH) | PAMAM dendrimer + immunogenic peptide Pep4 | Chlamydia trachomatis | Subcutaneous | Ganda et al., 2017 |
| Lipidated peptide dendrimers (TNS18) | Lipidated peptide dendrimers | Pseudomonas aeruginosa; Acinetobacter baumannii; methicillin-resistant Staphylococcus aureus Escherichia coli | Intraperitoneal | Siriwardena et al., 2018 |
| PAMAM dendrimer | PAMAM + platensimycin | methicillin-resistant Staphylococcus aureus | Intraperitoneal | Liu et al., 2020 |
| PAMAM dendrimers | peptide dendrimers | factor β-induced protein | Intravenous | Lee et al., 2020 |
| G2-S16 polyanionic carbosilane dendrimer | G2-S16 polyanionic carbosilane dendrimer | herpes simplex type 2 | Intravaginal | Guerrero-Beltrán et al., 2020 |
| PAMAM dendrimer | PAMAM dendrimer+azithromycin | Pseudomonas aeruginosa | Intratracheal | Gao et al., 2020 |
PAMAM: poly (amidoamine); PPI: poly (propylene imine); TNS18: peptide dendrimer; Cy5.5: used as the near-IR imaging agent; siRNA: small interfering RNA; (G4OH): dendrimer generation 4; Pep4: peptide of a chlamydial glycolipid antigen-Peptide 4; HIV-1: human immunodeficiency virus; G2-S16: polyanionic carbosilane dendrimer.